• Sign in

  • Join for free
  • Donate Today!
  • We are Social
    • Facebook
    • Twitter
    • Instagram
    • YouTube
    • LinkedIn
  • Who
    we are
    • Who we are
    • Our Story
    • Rosie
    • Rosie’s Blog
    • Our Trustees
    • Our Patrons
  • What
    we do
  • Secondary
    Breast Cancer
    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Your Stories
    • Where to go for information
  • Get
    involved
    • Our Fundraisers
    • How to fundraise
    • Events
      • Fonthill Open Garden Party
      • Past Events
  • News
    • News
    • In the media
    • Video
    • Rosie’s Blog
  • Contact
Secondary1st
  • Donate Today!

Search

Login

Register
  • 020 8905 3955info@secondary1st.org.uk
0
Secondary1st
  • Menu
  • Who
    we are
    • Who we are
    • Our Story
    • Rosie
    • Rosie’s Blog
    • Our Trustees
    • Our Patrons
  • What
    we do
  • Secondary
    Breast Cancer
    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Your Stories
    • Where to go for information
  • Get
    involved
    • Our Fundraisers
    • How to fundraise
    • Volunteer
    • Events
      • Fonthill Open Garden Party
      • Past Events
  • News & Media
    • News
    • In the media
    • Video
    • Rosie’s Blog
  • Contact
  • Donate Today!
25January

Tailored Treatments

Next
Previous
January 25, 2021
By cuco_admin_sec
0 Comment

NHS England has announced that it is rolling out a new blood test which aims to detect whether some cancer patients are genetically prone to experience more serious effects from some chemotherapy treatments.  These treatments can then be tailored more closely to the patients’ genetic makeup and so avoid the most serious side effects.

Drugs called Fluoropyramidines (including 5-fluorouracil, capecitabine and tegafur), which are used to treat some breast cancers, help to kill cancer cells and are usually broken down quickly by the liver and excreted.  However, some people whose livers do not produce enough of the enzyme DPD (dihydropyrimidine dehydrogenase) to break down these drugs in the body can suffer more serious side effects which can include diarrhoea, vomiting, breathlessness, nausea or extreme skin reactions.  The new genetic test will show if a patient is DPD deficient and so should receive a lower dose or even be given a different drug.  This marks another move towards the development of more personalised cancer treatments.

Categories: News
  • Search

  • Sign up for Newsletter

    * = required field
  • Categories

    • Event
    • Fundraising
    • In the media
    • News
    • Past Events
    • Rosie's blog
    • Uncategorised
    • Your Stories
  • Latest News

    • More Challenges for Tracey

      April 07, 2021

    • Up in the Air

      April 07, 2021

    • A More Efficient Treatment Method

      April 07, 2021

    • A Nice recommendation

      March 01, 2021

  • Who We Are

    • Who we are
    • Our Story
    • Rosie
    • Rosie’s blog
    • Our Trustees
    • Our Patrons
  • What We Do

    • What we do
  • Secondary Breast Cancer

    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Where to go for information
  • Get Involved

    • How to fundraise
    • Our Fundraisers

© 2016 - 2021 Secondary First is a Company Limited by Guarantee. Registered in England and Wales No. 9920657. Registered Office: 1st Floor Healthaid House, Marlborough Hill, Harrow, HA1 1UD. It is a Registered Charity Number 1165614.
Site maintained by CuCo Creative.

  • Cookie Policy
  • Privacy Policy